Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
|Slideshows|October 11, 2018
6 Myths About Integrative Psychiatry
Author(s)Scott Shannon, MD
As we shift from treating disease and toward supporting health, medication is merely one possible intervention in a spectrum of possible ones.
Advertisement
Advertisement
Related to this article
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
3
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5